In August, Rep. Alexandria Ocasio-Cortez’s public disclosure of her decision to freeze her eggs ignited a firestorm of national discourse. For many, the congresswoman’s choice was a landmark feminist act—a declaration of bodily autonomy in an era where reproductive rights are under constant siege. Yet, while the act itself is undeniably empowering for the individual, a critical question remains: Is the industry facilitating this choice truly feminist?
As an internal medicine physician specializing in health policy, I have spent years examining the intersection of care and commerce. My personal journey through the fertility industry, however, revealed a reality far removed from the narrative of "empowerment." Instead, I found an environment defined by body-shaming, financial opacity, and a "guess-and-check" medical model that prioritizes profit margins over patient well-being.
The Reality of the "Fertility Factory"
My entry into the fertility sector was prompted by the availability of employer-subsidized benefits. Like many women in their 30s, I sought a consultation to make an informed decision about my future. I approached the clinic with an open mind, viewing it as a standard health assessment.
The experience was jarring. Within minutes of entering the exam room, I was not treated as a patient with goals and values, but as a "cracked vessel." My doctor, focusing exclusively on age and hormone metrics, immediately pathologized my fertility. There was no inquiry into my life plans or reproductive aspirations; there was only the urgent, fear-based directive that my biological window was slamming shut.
This is the hallmark of the modern "fertility factory." By stoking anxiety, the industry pressures patients into high-cost procedures before they have time to evaluate their own desires or the actual efficacy of the intervention.
A Chronology of Clinical and Financial Entanglement
My journey was marred by systemic failures that extended far beyond the exam room:
- The Initial Consultation: Upon presenting, I was immediately steered toward a cycle of egg freezing based on "ticking clock" rhetoric rather than a holistic health conversation.
- The "Guess and Check" Protocol: I was informed that the medication dosing was largely experimental. This lack of precision resulted in significant logistical nightmares, including shipping delays of essential hormones that nearly forced me to abandon a cycle I had already paid thousands of dollars to initiate.
- The Billing Maze: Throughout the process, I faced a barrage of "surprise" charges. From inflated laboratory fees to a bizarre, unofficial demand for a $150 "Venmo payment" to a nurse for a trigger shot—a practice that borders on the unethical—the financial structure felt predatory.
- The Aftermath: Even after the procedure, the administrative burden persisted. I continue to pay a monthly storage fee, a reminder of a process that, while successful in technical terms, left me feeling alienated from my own reproductive health.
Supporting Data: The Financialization of Reproduction
The fertility industry is currently undergoing a rapid transformation driven by private equity and venture capital. According to a 2025 study in JAMA, the landscape of American fertility care is increasingly consolidated. In 14 states and Washington, D.C., more than 50% of clinics are backed by private equity, performing up to 100% of local IVF cycles.
This market concentration has profound implications for patient care:
- Market Growth: The global egg and embryo banking industry, valued at $4.49 billion in 2024, is projected to swell to $11.26 billion by 2030.
- Low Utilization Rates: A February study in the American Journal of Obstetrics and Gynecology revealed a sobering statistic: only 5.7% of patients who freeze their eggs return to use them within 5–7 years, with only 28.9% of those attempts resulting in live births.
- Research Gaps: Despite the high cost of treatment, research into women’s reproductive health remains underfunded. The share of NIH funds dedicated to women’s health actually dropped from 9.7% in 2013 to 7.9% in 2023, while conditions like endometriosis and polyendocrine metabolic ovarian syndrome—which have massive impacts on fertility—remain under-resourced and under-diagnosed.
Official Responses and Industry Defense
The fertility industry often defends its high costs and aggressive marketing as a response to the "complexity of modern reproductive medicine." However, the lack of transparency in billing remains a point of contention. Major organizations like Natera have faced class-action lawsuits regarding deceptive billing practices. While these firms often settle without admitting wrongdoing, the persistent pattern of "surprise bills" and coding errors continues to burden patients.
Advocates for the industry argue that increased access—even through employer subsidies—is a net positive. They contend that the growth of private equity allows for the scaling of infrastructure necessary to meet the rising demand for assisted reproductive technologies (ART). Yet, critics, including many medical ethicists, argue that this scale comes at the cost of the patient-physician relationship, transforming specialized medicine into a high-volume commodity.
The Broader Implications for Women’s Health
The implications of this industry structure are far-reaching. By relying on employer subsidies rather than universal, regulated coverage, we create a tiered system that favors the wealthy and leaves marginalized populations behind.
1. The Erosion of Informed Consent
When providers use fear-based marketing to push elective procedures, they erode the foundations of informed consent. Patients are often not adequately warned of the physical risks associated with hormonal hyperstimulation or the emotional toll of unsuccessful IVF cycles.
2. The Need for Structural Reform
If we are to align the fertility industry with feminist values, we must pivot from a model of "fertility preservation as a product" to "reproductive health as a right." This requires:
- Increased Transparency: Ending the "guess-and-check" billing culture and mandating clear, upfront pricing that includes all auxiliary costs.
- Robust Regulation: Breaking up the private equity monopolies that drive up costs and prioritize high-volume, impersonal service over patient-centered care.
- Public Policy Shifts: Moving away from employer-based, fragmented models toward state or federal insurance coverage for fertility services. This would normalize reproductive care and ensure that access is not tied to one’s job title or company policy.
3. Redefining "Choice"
True reproductive choice is not just about the ability to freeze one’s eggs; it is about having access to a health system that supports a person’s total reproductive life cycle. This includes better research into the conditions that actually cause infertility, improved education for primary care providers to identify these conditions early, and a cultural shift that moves away from the idea that a woman’s body is a depreciating asset that must be "saved" through expensive, unproven, or excessive intervention.
Conclusion: A Call for an Honest Conversation
As I reflect on my own journey, I recognize the immense privilege I held in being able to navigate this system. I do not regret my decision to freeze my eggs, but I am deeply troubled by the path it required me to take.
The current state of the fertility industry is a reflection of a healthcare system that has lost its way, prioritizing the financialization of human biology over the health and autonomy of the individual. If we are to honor the spirit of the current debate—the spirit of true autonomy and empowerment—we must stop treating fertility as a luxury good and start demanding a system that is transparent, accessible, and deeply respectful of the people it serves.
We owe it to the next generation of patients to replace the "fertility factory" with a model of care that is, in every sense of the word, feminist.
Pooja Yerramilli, M.D., is a clinical assistant professor at NYU Grossman School of Medicine. She has previously worked at the World Bank, the World Health Organization, and various nongovernmental organizations on improving affordable access to high-quality health care and public health.
